The company's proprietary dually derived chitosan (DDX) platform allows for flexible delivery of nucleic acid payloads to mucosal tissues, with applications in various diseases and tissues. enGene is focused on developing genetic medicines for respiratory indications and is also exploring applications in nasal, genital, and gastrointestinal mucosa. Supported by top-tier institutional investors, enGene aims to develop mucosal immunotherapy platforms for chronic diseases such as inflammatory bowel disease and diabetes, using their non-integrating biopolymer-based nucleotide delivery technology.